Drugs / GR2301 injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07190716 | Oct 2025 → May 2026 overdue | — | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR2301 injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07190716 ↗ |
| Route | Subcutaneous | “All healthy subjects will receive a single subcutaneous injection.” NCT07190716 ↗ |